About Phenocell
Phenocell: Revolutionizing Dermatology and Ophthalmology Preclinical R&D
Phenocell is a leading preclinical research and development company that specializes in dermatology and ophthalmology. The company has been at the forefront of innovation, using the Nobel-Prize winning Technology of iPSC to produce first-in-time phenotypic bioassays. With highly relevant set-ups that perfectly match human pathophysiological conditions, Phenocell offers an easy and quick way to validate drug activity or scientific claims.
The company's mission is to provide innovative solutions for preclinical research in dermatology and ophthalmology. Phenocell's team of experts works tirelessly to develop new technologies that can help researchers better understand diseases, identify potential treatments, and accelerate drug discovery.
One of the key advantages of working with Phenocell is their use of iPSC technology. This cutting-edge technology allows researchers to generate patient-specific cells from skin or blood samples. These cells can then be differentiated into various cell types, including those found in the skin or eye. By using these cells in phenotypic assays, researchers can gain a better understanding of disease mechanisms and test potential therapies more accurately.
Phenocell offers a range of services designed to meet the needs of pharmaceutical companies, biotech firms, academic institutions, and other organizations involved in preclinical research. Their services include:
1) Customized Assay Development: Phenocell develops customized assays tailored to specific research needs. These assays are designed based on disease-relevant endpoints using human primary cells or iPSC-derived cell models.
2) Compound Screening: The company provides high-throughput screening services for compound libraries against various targets relevant for dermatological or ophthalmological indications.
3) Disease Modeling: Using patient-derived iPSCs as well as CRISPR/Cas9 gene editing technology; they create cellular models for rare genetic disorders such as ichthyosis vulgaris, epidermolysis bullosa, and retinitis pigmentosa.
4) Phenotypic Profiling: Phenocell offers phenotypic profiling services to evaluate the efficacy of compounds in relevant disease models. This service includes a comprehensive analysis of cellular morphology, gene expression, and protein localization.
5) Toxicity Testing: The company provides toxicity testing services to assess the safety of compounds in relevant cell models. This service includes a range of assays designed to evaluate cytotoxicity, genotoxicity, and other potential toxicities.
Phenocell's team is composed of highly skilled scientists with extensive experience in preclinical research. They work closely with clients to understand their specific needs and develop customized solutions that meet their requirements. The company's state-of-the-art facilities are equipped with cutting-edge technologies that enable them to deliver high-quality results quickly and efficiently.
In conclusion, Phenocell is a dedicated dermatology and ophthalmology preclinical R&D company that offers innovative solutions for drug discovery. Their use of iPSC technology allows researchers to generate patient-specific cells for disease modeling and compound screening. With customized assay development services tailored to specific research needs as well as phenotypic profiling and toxicity testing capabilities; they provide an easy way for researchers to validate drug activity or scientific claims accurately. If you're looking for a reliable partner in preclinical research; Phenocell is the right choice!